Unmanipulated Haploidentical Bone Marrow Transplantation and Posttransplantation Cyclophosphamide for Hematologic Malignancies after Myeloablative Conditioning

Anna Maria Raiola, Alida Dominietto, Anna Ghiso, Carmen Di Grazia, Teresa Lamparelli, Francesca Gualandi, Stefania Bregante, Maria Teresa Van Lint, Simona Geroldi, Silvia Luchetti, Filippo Ballerini, Maurizio Miglino, Riccardo Varaldo, Andrea Bacigalupo

Research output: Contribution to journalArticlepeer-review

Abstract

Fifty patients with high-risk hematologic malignancies, underwent an unmanipulated haploidentical bone marrow transplantation (BMT), followed by posttransplantation high-dose cyclophosphamide (PT-CY): the myeloablative (MA) conditioning consisted of thiotepa, busulfan, fludarabine (n = 35), or total body irradiation (TBI), fludarabine (n = 15). The median age was 42 years (range, 18-66 years); 23 patients were in remission, 27 had active disease, and 10 patients were receiving a second allograft. Graft-versus-host disease (GVHD) prophylaxis consisted in PT-CY on day +3 and +5, cyclosporine (from day 0), and mycophenolate (from day +1). Three patients died before engraftment, and 2 patients had autologous recovery: 45 patients (90%) had full-donor chimerism on day +30. The median day for neutrophil engraftment was day +18 (range, 13-30 days). The cumulative incidence of grade II-III acute GVHD (aGVHD) was 12%, and of moderate chronic GVHD (cGVHD) 10%. With a median follow-up for surviving patients of 333 days (range, 149-623 days), the cumulative incidence of transplantation-related mortality (TRM) was 18%, and the rate of relapse was 26%. The actuarial 22-month disease-free survival (DFS) rate was 68% for patients in remission and 37% for patients with active disease (P <.001). Causes of death were pneumonia (n = 3), hemorrhage (n = 3), sepsis (n = 3), and relapse (n = 7). In conclusion, an MA conditioning regimen followed by haploidentical BMT with PT-CY results in a low risk of aGVHD and cGVHD and encouraging rates of TRM and DFS.

Original languageEnglish
Pages (from-to)117-122
Number of pages6
JournalBiology of Blood and Marrow Transplantation
Volume19
Issue number1
DOIs
Publication statusPublished - Jan 2013

Keywords

  • Acute leukemia
  • Allogeneic stem cell transplant
  • Haploidentical transplantations
  • HLA
  • Posttransplantation cyclophosphamide

ASJC Scopus subject areas

  • Transplantation
  • Hematology

Fingerprint

Dive into the research topics of 'Unmanipulated Haploidentical Bone Marrow Transplantation and Posttransplantation Cyclophosphamide for Hematologic Malignancies after Myeloablative Conditioning'. Together they form a unique fingerprint.

Cite this